Markets Insider: BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease Nasdaq: BioRestorative Therapies, Inc. Receives FDA Fast Track Designation for BRTX-100 in Chronic Lumbar Disc Disease BioRestorative Therapies, Inc. announced that the U.S.
Food and Drug Administration (FDA) has granted Fast Track designation to its BRTX-100 program for treating chronic lumbar disc disease (cLDD). BioRestorative Therapies, Inc. Receives FDA Fast Track Designation for BRTX-100 in Chronic Lumbar Disc Disease Detroit Free Press: Longevity Medical Institute® Publishes Research on Intradiscal Stem Cell Therapy for Degenerative Disc Disease Longevity Medical Institute® Publishes Research on Intradiscal Stem Cell Therapy for Degenerative Disc Disease Hydatid disease is a parasitic zoonosis caused primarily by the larval stage of Echinococcus granulosus. It is endemic in many pastoral regions and typically manifests in the liver and lungs.
